Amgen Inc (AMGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $251.89B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amgen Inc (AMGN) Financials: Revenue, Profit and Cash Flow
Amgen reported revenue of $36.75B for the fiscal year ended Dec 31, 2025, up 10.0% from the year before. That year, net income was $7.71B with a net margin of 21.0%, operating cash flow was $9.96B and free cash flow was $8.10B. The quarter ended Sep 30, 2026 had revenue of $10.37B and net income of $3.86B.
Revenue and Margins
The operating margin was 24.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $22.99B, a compound annual rate of 5.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $36.75B | +10.0% | 67.2% | 24.7% | 21.0% |
| Dec 2024 | $33.42B | +18.6% | 61.5% | 21.7% | 12.2% |
| Dec 2023 | $28.19B | +7.1% | 70.0% | 28.0% | 23.8% |
| Dec 2022 | $26.32B | +1.3% | 75.7% | 36.3% | 24.9% |
| Dec 2021 | $25.98B | +2.2% | 75.2% | 29.4% | 22.7% |
| Dec 2020 | $25.42B | +8.8% | 75.8% | 35.9% | 28.6% |
| Dec 2019 | $23.36B | -1.6% | 81.4% | 41.4% | 33.6% |
| Dec 2018 | $23.75B | +3.9% | 82.7% | 43.2% | 35.3% |
| Dec 2017 | $22.85B | -0.6% | 82.2% | 43.6% | 8.7% |
| Dec 2016 | $22.99B | N/A | 81.9% | 42.6% | 33.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 88.5% from the year before. In the quarter ended Sep 2026, net income rose 19.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B | $23.36B | $23.75B | $22.85B | $22.99B |
| Cost of revenue | $12.04B | $12.86B | $8.45B | $6.41B | $6.45B | $6.16B | $4.36B | $4.10B | $4.07B | $4.16B |
| Gross profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.52B | $19.27B | $19.01B | $19.65B | $18.78B | $18.83B |
| Research and development | $7.27B | $5.96B | $4.78B | $4.43B | $6.32B | $4.21B | $4.12B | $3.74B | $3.56B | $3.84B |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B | $9.14B | $9.67B | $10.26B | $9.97B | $9.79B |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B | $7.72B |
| EBITDA | $16.90B | $13.36B | $14.80B | $12.17B | $11.30B | $13.00B | $12.63B | $12.88B | $12.86B | $12.53B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.37B | $10.05B | $8.62B | $9.87B | $9.56B | $9.18B | $8.15B | $9.09B | $8.50B | $8.39B | $7.45B | $8.20B |
| Gross profit | $7.58B | $7.24B | $5.87B | $6.89B | $6.47B | $6.17B | $5.18B | $5.97B | $5.19B | $5.15B | $4.25B | $5.08B |
| Operating income | $3.71B | $3.51B | $2.67B | $2.72B | $2.53B | $2.66B | $1.18B | $2.31B | $2.05B | $1.91B | $991.00M | $1.27B |
| Net income | $3.86B | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | $1.73B | $627.00M | $2.83B | $746.00M | -$113.00M | $767.00M |
Balance Sheet
As of Dec 2025, total debt of $54.60B exceeded cash and equivalents by $45.48B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $90.59B | $91.84B | $97.15B | $65.12B | $61.16B | $62.95B | $59.71B | $66.42B | $79.95B | $77.63B |
| Current assets | $29.06B | $29.03B | $30.33B | $22.19B | $19.39B | $21.14B | $18.44B | $37.62B | $49.48B | $46.01B |
| Cash and equivalents | $9.13B | $11.97B | $10.94B | $7.63B | $7.99B | $6.27B | $6.04B | $6.95B | $3.80B | $3.24B |
| Total liabilities | $81.93B | $85.96B | $90.92B | $61.46B | $54.47B | $53.54B | $50.03B | $53.92B | $54.71B | $47.75B |
| Short-term debt | $4.60B | $3.55B | $1.44B | $1.59B | $87.00M | $91.00M | $2.95B | $4.42B | $1.15B | $4.40B |
| Long-term debt | $50.01B | $56.55B | $63.17B | $37.35B | $33.22B | $32.90B | $26.95B | $29.51B | $34.19B | $30.19B |
| Shareholder equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.70B | $9.41B | $9.67B | $12.50B | $25.24B | $29.88B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $96.05B | $95.64B | $92.50B | $90.59B | $90.14B | $87.90B | $89.37B | $91.84B | $90.88B | $90.91B | $92.98B | $97.15B |
| Total liabilities | $81.70B | $83.95B | $83.31B | $81.93B | $80.52B | $80.47B | $83.16B | $85.96B | $83.36B | $84.98B | $87.96B | $90.92B |
| Cash and equivalents | $13.19B | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | $8.81B | $11.97B | $9.01B | $9.30B | $9.71B | $10.94B |
| Shareholder equity | $14.35B | $11.69B | $9.19B | $8.66B | $9.62B | $7.43B | $6.21B | $5.88B | $7.53B | $5.92B | $5.02B | $6.23B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 81.3% of operating cash flow. Dividends came to 63.2% of it, with no share repurchases.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.96B | $11.49B | $8.47B | $9.72B | $9.26B | $10.50B | $9.15B | $11.30B | $11.18B | $10.35B |
| Capital expenditures | $1.86B | $1.10B | $1.11B | $936.00M | $880.00M | $608.00M | $618.00M | $738.00M | $664.00M | $738.00M |
| Free cash flow | $8.10B | $10.39B | $7.36B | $8.79B | $8.38B | $9.89B | $8.53B | $10.56B | $10.51B | $9.62B |
| Dividends paid | $5.12B | $4.83B | $4.56B | $4.20B | $4.01B | $3.75B | $3.51B | $3.51B | $3.37B | $3.00B |
| Share repurchases | $0 | $200.00M | $0 | $6.36B | $4.97B | $3.49B | $7.70B | $17.79B | $3.16B | N/A |
| Investing cash flow | -$1.94B | -$1.05B | -$26.20B | -$6.04B | $733.00M | -$5.40B | $5.71B | $14.34B | -$4.02B | -$8.66B |
| Financing cash flow | -$10.86B | -$9.41B | $21.05B | -$4.04B | -$8.27B | -$4.87B | -$15.77B | -$22.49B | -$6.59B | -$2.60B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.24B | $4.00B | $2.19B | $1.60B | $4.68B | $2.28B | $1.39B | $4.77B | $3.57B | $2.46B | $689.00M | $538.00M |
| Capital expenditures | $587.00M | $513.00M | $712.00M | $642.00M | $436.00M | $369.00M | $411.00M | $371.00M | $257.00M | $238.00M | $230.00M | $249.00M |
| Free cash flow | $3.65B | $3.49B | $1.48B | $961.00M | $4.25B | $1.91B | $980.00M | $4.40B | $3.31B | $2.22B | $459.00M | $289.00M |
Frequently Asked Questions About AMGN
What is Amgen's annual revenue?
Amgen reported revenue of $36.75B for the fiscal year ended Dec 31, 2025.
How fast is Amgen's revenue growing?
Revenue was up 10.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 11.8%.
Is Amgen profitable?
Yes. Amgen reported net income of $7.71B for the fiscal year ended Dec 31, 2025, with a net margin of 21.0%.
How much free cash flow does AMGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $9.96B minus capital expenditures of $1.86B produced free cash flow of $8.10B.
How much debt does Amgen have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $50.01B, short-term debt of $4.60B and cash and equivalents of $9.13B.
AMGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts